These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21517672)

  • 1. Use of recombinant factor VIIa (NovoSeven(®)) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux.
    Luporsi P; Chopard R; Janin S; Racadot E; Bernard Y; Ecarnot F; Séronde MF; Briand F; Guignier A; Descotes-Genon V; Meneveau N; Schiele F
    Acute Card Care; 2011 Jun; 13(2):93-8. PubMed ID: 21517672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants.
    Vavra KA; Lutz MF; Smythe MA
    Ann Pharmacother; 2010 Apr; 44(4):718-26. PubMed ID: 20233918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
    Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
    J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study.
    Skolnick BE; Shenouda M; Khutoryansky NM; Pusateri AE; Gabriel D; Carr ME
    Anesth Analg; 2011 Oct; 113(4):703-10. PubMed ID: 21890888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
    Anderson JA; Hirsh J; Yusuf S; Johnston M; Afzal R; Mehta SR; Fox KA; Budaj A; Eikelboom JW
    J Thromb Haemost; 2010 Feb; 8(2):243-9. PubMed ID: 19943881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of fondaparinux in the prevention of venous thromboembolism in elderly medical patients: results of a single-center, retrospective study.
    Silvestri F; Pasca S; Labombarda A; Barbi A; Desideri M; Guidi P; Rogato A; Zaramella M; Bergamo M; Ageno W; Barillari G
    Minerva Med; 2014 Jun; 105(3):221-8. PubMed ID: 24988087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.
    Bijsterveld NR; Moons AH; Boekholdt SM; van Aken BE; Fennema H; Peters RJ; Meijers JC; Büller HR; Levi M
    Circulation; 2002 Nov; 106(20):2550-4. PubMed ID: 12427650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials.
    Johansson PI
    Vox Sang; 2008 Jul; 95(1):1-7. PubMed ID: 18435677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of fondaparinux sodium for the treatment of venous thromboembolism.
    Mastroiacovo D; Sala G; Dentali F
    Expert Opin Drug Saf; 2016 Sep; 15(9):1259-65. PubMed ID: 27537418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid.
    Huvers F; Slappendel R; Benraad B; van Hellemondt G; van Kraaij M
    Neth J Med; 2005 May; 63(5):184-6. PubMed ID: 15952489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.
    Cohen AT; Davidson BL; Gallus AS; Lassen MR; Prins MH; Tomkowski W; Turpie AG; Egberts JF; Lensing AW;
    BMJ; 2006 Feb; 332(7537):325-9. PubMed ID: 16439370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events.
    Ko RH; Michieli C; Lira JL; Young G
    Thromb Res; 2014 Sep; 134(3):643-7. PubMed ID: 25087891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NovoSeven in warfarin-treated patients.
    Berntorp E; Stigendal L; Lethagen S; Olofsson L; Hedner U
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S113-5. PubMed ID: 10850575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
    Karthikeyan G; Mehta SR; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):241-9. PubMed ID: 19296760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage.
    Hauser CJ; Boffard K; Dutton R; Bernard GR; Croce MA; Holcomb JB; Leppaniemi A; Parr M; Vincent JL; Tortella BJ; Dimsits J; Bouillon B;
    J Trauma; 2010 Sep; 69(3):489-500. PubMed ID: 20838118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
    Mehta SR; Steg PG; Granger CB; Bassand JP; Faxon DP; Weitz JI; Afzal R; Rush B; Peters RJ; Natarajan MK; Velianou JL; Goodhart DM; Labinaz M; Tanguay JF; Fox KA; Yusuf S;
    Circulation; 2005 Mar; 111(11):1390-7. PubMed ID: 15781750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.